MedeliX
Start asking

ibandronic acid

Bondronat, Bonviva · ATC code M05BA06

Also known as: Ibandronsäure, İbandronik asit · Brand names: Bondronat, Bonviva, Ibandronsäure Ratiopharm, Ibandronsäure Sandoz, Ibandronsäure Stada, Osteonat, Osteoviva, Ibandronate Bluefish, Ibandronsäure Al, Ibandronsäure Beta, Ibandronsäure Cell Pharm, Beos, Bondkem, Bonmore, Fixbone …

Key facts
Active substance
ibandronic acid
ATC code
M05BA06
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Bondronat 2 mg concentrate for solution for infusion. · Bondronat 50 mg film-coated tablets. · Bondronat 6 mg concentrate for solution for infusion. · Bonviva 150 mg film-coated tablets · Bonviva 3 mg solution for injection
Marketing authorisation holder
Atnahs Pharma Netherlands B.V.
Information as of
2026-10-28

Key facts

Ibandronic acid is a bisphosphonate that inhibits bone resorption. It is used for postmenopausal osteoporosis and for breast cancer with bone metastases and tumour-induced hypercalcaemia.

What it is used for

  • Bondronat (infusion and tablets): prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in adults with breast cancer and bone metastases.
  • Bondronat (infusion): treatment of tumour-induced hypercalcaemia with or without metastases.
  • Bonviva (tablets and injection): treatment of osteoporosis in postmenopausal women at increased risk of fracture; reduction in vertebral fracture risk demonstrated.

Dosing

  • Bondronat infusion, bone metastases: 6 mg every 3-4 weeks, infused over at least 15 minutes (the short infusion time only with normal renal function or mild impairment). For renal impairment see the full text.
  • Bondronat infusion, tumour-induced hypercalcaemia: after adequate rehydration, 4 mg as a single dose in most patients with severe hypercalcaemia, 2 mg in moderate hypercalcaemia.
  • Bondronat 50 mg film-coated tablets: one tablet daily; moderate renal impairment (CLcr ≥30 and <50 mL/min) every second day, severe (CLcr <30 mL/min) once weekly.
  • Bonviva 150 mg film-coated tablets: one tablet once a month after an overnight fast (at least 6 hours) and 1 hour before the first food or drink; not recommended with creatinine clearance below 30 ml/min.
  • Bonviva 3 mg solution for injection: 3 mg intravenously over 15 - 30 seconds every three months, with calcium and vitamin D; not recommended with creatinine clearance below 30 ml/min.
  • Tablets: swallow whole upright with a glass of plain water, do not chew or suck; do not lie down for 60 minutes afterwards.

Contraindications

  • Hypersensitivity to ibandronic acid or to any of the excipients; hypocalcaemia.
  • Tablets additionally: oesophageal abnormalities delaying emptying (e.g. stricture, achalasia); inability to stand or sit upright for at least 60 minutes.

Important warnings

  • Correct existing hypocalcaemia before starting; ensure adequate calcium and vitamin D intake.
  • Oral use: upper gastrointestinal irritation, oesophagitis and oesophageal ulcers; follow the dosing instructions strictly.
  • Osteonecrosis of the jaw and of the external auditory canal; atypical femoral fractures, mainly with long-term treatment – report thigh, hip or groin pain.
  • Intravenous use: anaphylactic reaction/shock, including fatal events; avoid intra-arterial or paravenous administration.
  • In osteoporosis, re-evaluate the need for continued treatment periodically, particularly after 5 or more years.

Side effects

  • Most frequent (osteoporosis): arthralgia and influenza-like symptoms, usually with the first dose, short-lived and mild or moderate.
  • Hypercalcaemia treatment: most frequently a rise in body temperature.
  • Serious: anaphylactic reaction/shock, atypical femoral fractures, osteonecrosis of the jaw, ocular inflammation, gastrointestinal irritation (tablets).

Interactions

  • Tablets: food, milk and products containing calcium or other multivalent cations (aluminium, magnesium, iron) reduce absorption; keep the fasting interval.
  • Metabolic interactions via cytochrome P450 are not considered likely.

Pregnancy and breastfeeding

  • Bonviva is only for postmenopausal women and must not be taken by women of childbearing potential; not to be used during pregnancy.
  • Bondronat: for pregnancy and breast-feeding see the full text.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Austria

  • Ibandronsäure RatiopharmTeva B.V · 1 register entry
  • Ibandronsäure SandozSandoz Gmbh · 1 register entry
  • Ibandronsäure StadaStada Arzneimittel Gmbh · 1 register entry
  • OsteonatG.L. Pharma Gmbh · 1 register entry
  • OsteovivaG.L. Pharma Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

  • Ibandronate BluefishBluefish Pharmaceuticals Ab · 1 register entry
  • Ibandronsäure AlAliud Pharma Gmbh · 2 register entries
  • Ibandronsäure BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Ibandronsäure Cell PharmStadapharm Gmbh · 1 register entry
  • Ibandronsäure RatiopharmRatiopharm Gmbh · 2 register entries
  • Ibandronsäure StadaStadapharm Gmbh · 2 register entries

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • BeosPOLPHARMA SAĞLIK ÜRÜNLERİ SAN. VE TİC. A.Ş., ARDİ FARMA İLAÇ PAZARLAMA TİC. LTD. ŞTİ. · 4 register entries
  • BondkemGENVEON İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • BondronatALİ RAİF İLAÇ SAN. A.Ş. · 4 register entries
  • BonmoreKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 1 register entry
  • BonvivaALİ RAİF İLAÇ SAN. A.Ş. · 4 register entries
  • FixboneNEUTEC İLAÇ SAN. TİC. A.Ş · 1 register entry
  • GauditARDİ FARMA İLAÇ PAZARLAMA TİC. LTD. ŞTİ. · 1 register entry
  • IbacurNEUTEC İLAÇ SAN. TİC. A.Ş · 3 register entries
  • IbamaxNEUTEC İLAÇ SAN. TİC. A.Ş · 1 register entry
  • IbanosGENVEON İLAÇ SAN. VE TİC. A.Ş. · 3 register entries
  • IbofixBİLİM İLAÇ SAN. VE TİC. A.Ş. · 2 register entries
  • OsibanKOÇAK FARMA İLAÇ VE KİMYA SAN. A.Ş. · 1 register entry
Show all 13 brand names
  • SempribanSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 26 more European countries
Belgium
Ibandronate Eg
Bulgaria
Ибандронова Киселина Синтон, Ибандронова Киселина Стада
Croatia
Bonnedra, Bonosta, Ibadron, Ibandronat Pharmas, Ibandronat Sandoz, Ibat
Czechia
Gerousia, Ikametin, Osagrand
Denmark
Baxogar, Ibamyl, Ibandronat Stada
Estonia
Bonefurbit, Ibandronic Acid Synthon
Finland
Clastec, Ibandronat Stada, Ibandronate Ratiopharm
Greece
Axibal, Ibanate, Ibosat, Sedropor, Voliran
Hungary
Ibandronate Pharmacenter, Ibandronsav Stada
Iceland
Ibandronic Acid Accord, Ibandronic Acid Alvogen, Ibandronic Acid Teva, Ibandronic Acid Wh
Ireland
Ibandronic Acid Accord Healthcare Ireland, Ibandronic Acid Clonmel, Ibandronic Acid Viatris
Italy
Acido Ibandronico Alter, Acido Ibandronico Aurobindo, Acido Ibandronico Doc Generici, Acido Ibandronico Eg, Acido Ibandronico Pensa, Acido Ibandronico Sandoz, Baxogar
Latvia
Ibandronic Acid Ratiopharm, Ibandronic Acid Synthon
Liechtenstein
Ibandronic Acid Accord, Ibandronic Acid Teva
Lithuania
Bonefurbit, Ibandronic Acid Ingen Pharma, Ibandronic Acid Ratiopharm
Luxembourg
Ibandronate Eg
Malta
Ibandronic Acid Aurobindo
Netherlands
Baxogar, Ibandronic Acid Aurobindo, Ibandroninenzuur Mylan, Ibandroninezuur Genthon, Ibandroninezuur Ratiopharm, Ibandroninezuur Sandoz, Ibandroninezuur Synthon, Ibandroninezuur Teva, Ikametin
Norway
Axibal, Bonefurbit, Ibandronic Acid Accord, Ibandronic Acid Activase Pharmaceuticals, Ibandronic Acid Teva, Ibandronsyre Liconsa, Kefort, Licobondrat, Ratiban, Vinodran
Poland
Ibandronic Acid Aurovitas, Ibandronic Acid Synthon, Kefort, Osagrand
Portugal
Acido Ibandronico Tecnigen, Baxogar, Quodixor, Ácido Ibandrónico Alter, Ácido Ibandrónico Aurobindo, Ácido Ibandrónico Bluefish, Ácido Ibandrónico Bluepharma, Ácido Ibandrónico Bluesar, Ácido Ibandrónico Ciclum, Ácido Ibandrónico Farmoz, Ácido Ibandrónico Generis, Ácido Ibandrónico Pentafarma, Ácido Ibandrónico Pharmakern, Ácido Ibandrónico Ratiopharm, Ácido Ibandrónico Synthon, Ácido Ibandrónico Tolife, Ácido Ibandrónico Viatris, Ácido Ibandrónico Vitória
Romania
Acid Ibandronic Stada
Slovakia
Gerousia, Ibandronic Acid Stada, Ibandronic Acid Viatris, Phacebonate
Slovenia
Ibandronska Kislina Synthon
Spain
Abrion, Ácido Ibandrónico Alter, Ácido Ibandrónico Aurovitas, Ácido Ibandrónico Bluefish, Ácido Ibandrónico Cinfa, Ácido Ibandrónico Kern Pharma, Ácido Ibandrónico Normon, Ácido Ibandrónico Pensa, Ácido Ibandrónico Qualigen, Ácido Ibandrónico Ratiopharm, Ácido Ibandrónico Sandoz, Ácido Ibandrónico Stada, Ácido Ibandrónico Tarbis, Ácido Ibandrónico Tecnigen, Ácido Ibandrónico Viatris, Ácido Ibandrónico Vir
Sweden
Ibandronat Stada

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Bondronat – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/bondronat-epar-product-information_en.pdf
  2. European Medicines Agency. Bonviva – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/bonviva-epar-product-information_en.pdf
  3. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  5. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.